ASCO: Targeted cancer drugs wait in
Sets the scene for the annual meeting of the American Society of Clinical Oncology (ASCO) which kicks off June 5 in New Orleans. Up for discussion: new data that will be presented on a number of targeted therapies under development as well as some that have already been approved for late-stage cancers but are being tested to see if they'll work well as earlier treatment options or as part of combination treatments. The expected darling of the meeting, says the story: Tarceva. The article includes info on some of the data that's already been released and highlights data on Avastin, Erbitux and panitumumab, a promising treatment being developed by Amgen and Abgenix that's currently in Phase III trials and about which the companies will be releasing new study data at the ASCO meeting.
Wall Street Journal (sub req)